Multicenter analysis of influence of Helicobacter pylori eradication on chronic gastritis
10.3760/cma.j.issn.1007-5232.2011.08.006
- VernacularTitle:根除幽门螺杆菌感染对慢性胃炎疗效影响的多中心临床研究
- Author:
Jun FANG
;
Yiqi DU
;
Zhiqiang SONG
;
Liya ZHOU
;
Sanren LIN
;
Xiaohua HOU
;
Sanping XU
;
Minhu CHEN
;
Lishou XIONG
;
Yanfang GONG
;
Huagao ZHANG
;
Li GAO
;
Zhaoshen LI
- Publication Type:Journal Article
- Keywords:
Gastritis;
Helicobacter pylori;
Gastric mucosa;
Endoscopy
- From:
Chinese Journal of Digestive Endoscopy
2011;28(8):433-437
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the influence of Helicobacter pylori (Hp) eradication on clinical manifestations, endoscopic features and pathological findings of chronic gastritis. Methods This was a multiple-center, prospective and randomized cohort study. Patients with non-atrophy chronic gastritis from January 2009 to December 2010 were randomized into 3 groups as Hp positive group with eradication, Hp positive group without eradication and Hp negative group. Clinical manifestations, endoscopic findings and pathologic changes of inflammation were compared before and after administration of gastric mucosal protective agent for 8 weeks. Results A total of 211 patients were recruited. Changes of symptom score, endoscopic erosion and mucosal inflammation were significantly different before and after treatment in 3 groups. The decrease in symptom scores of eradication group was ( 3.56 ± 1.37 ), which was significantly higher than that of non-eradication group (2. 80 ± 1.30, P ＜0. 01 ). The decrease of mucosal inflammation and inflammatory activity scores in eradicate group was 1.08 ± 1.34 and 1.42 ± 1.09, respectively, which were also significantly higher than those of the eradication group (0. 49 ± 1.47 and 0. 61 ± 1.34, P ＜0. 01 ). But the improvement of endoscopic erosion in 2 groups showed no significant difference. There were no significant differences in these variables between non-eradication group and Hp-negative group ( P ＞ 0. 05 ). Conclusion For chronic non-atrophic gastritis patients with positive Hp infection, combination of mucosal protective agents and Hp eradication can achieve better improvement in symptoms and gastric inflammation repair.
